Almirall (LBTSF) Stock Price, News & Analysis

Company Overview

Almirall, S.A. is a Spanish pharmaceutical company focused on researching, developing and commercializing medicines for dermatological conditions. The company serves healthcare professionals and patients primarily through prescription therapies designed to address diseases affecting the skin.

Its portfolio and research activities cover areas such as acne, psoriasis, atopic dermatitis, actinic keratosis and other inflammatory, infectious or medically significant skin disorders. Almirall also develops and commercializes treatments through internal research, licensing arrangements and strategic partnerships.

Founded in 1943 by the Gallardo family, Almirall is headquartered in Barcelona, Spain. The company operates internationally, with a presence across Europe and in other selected markets, including the United States. Carlos Gallardo has served as the company’s chief executive officer.

Key Stats

• Today's Range: $15.35 to $15.35
• 50-Day Range: $15.35 to $15.35
• 52-Week Range: $13.36 to $15.47
• Volume: N/A
• Average Volume: 200 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Almirall Stock Analysis - MarketRank™

Almirall scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Almirall has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Almirall has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Almirall is -205.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Almirall is -205.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Almirall has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Almirall has recently increased by 0.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Almirall does not currently pay a dividend.

Dividend Growth

Almirall does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Almirall insiders have not sold or bought any company stock.

Percentage Held by Institutions

16.10% of the stock of Almirall is held by institutions.

Company Calendar

• Today: 9/23/2026
• Next Earnings (Estimated): 11/09/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:LBTSF
• CIK: N/A
• Web: www.almirall.com
• Phone: 34 93 291 30 00
• Fax: N/A
• Employees: 1,996
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A